Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + Anlotinib Maintenance in LS-SCLC
NCT05942508Phase 1Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of benmelstobart and anlotinib in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoints: Adverse event and serious adverse event. Started May 2023; status: recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05942508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942508.